BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June

Day

• 2
• 3
• 4
• 5
• 6
• 7
• 10
• 11
• 12
• 13
• 14
• 17
• 18
• 19
• 20
• 21
• 24
• 25
• 26
• 27
• 28
• 31

• 

  William Soliman

  William Soliman is the founder and CEO of the Accreditation Council for Medical Affairs (ACMA), a provider of life sciences accreditation, certification and training. He previously worked in leadership roles at companies such as Merck, Abbvie and Gilead.
• 

  Sarfaraz K. Niazi

  Sarfaraz K. Niazi, Ph.D., is an adjunct professor at the University of Illinois and University of Houston, CEO of RNA Therapeutics and CTO of ABYOLO, companies developing biological drugs. ABYOLO is specifically focused on biosimilars.
• 

  Collaboration

  AstraZeneca Sets Sights and $1.35B on Subcutaneous Cancer Drugs With Alteogen Alliance

  Monday was a busy day for AstraZeneca, which also paid up to $1 billion to acquire Belgian biotech EsoBiotec and its cell therapy pipeline and technology.

  March 18, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  NextGen

  Mirador Pursues All Options To Be 2030’s Greatest I&I Breakthrough

  Mirador debuted last year with a massive $400 million and the goal of developing game-changing therapies for inflammatory and fibrotic diseases. The company aims to enter the clinic this year.

  March 18, 2025

   · 

  3 min read

   · 

  Annalee Armstrong
• 

  Podcast

  A Conversation With Mark McKenna, CEO of Mirador

  In the third podcast in a special series focused on BioSpace’s NextGen Class of 2025, Senior Editor Annalee Armstrong speaks with Mark McKenna, CEO of Mirador Therapeutics.

  March 18, 2025

   · 

  1 min read

   · 

  Annalee Armstrong
• 

  GLP-1

  OPKO and Entera Link Up to Advance First Oral GLP-1/Glucagon Drug Into Clinic

  Under the terms of the agreement, OPKO will accept 60% of the development costs, while Entera will shoulder 40%.

  March 18, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Gene Therapy

  Sarepta Shares Crash 22% After Patient on DMD Gene Therapy Elevidys Dies

  After a patient taking the Duchenne muscular dystrophy gene therapy Elevydis died of liver injury, Sarepta will update the label to reflect the safety signal.

  March 18, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Gene editing

  Arbor Raises $73.5M To Ride Out Gene Editing’s ‘Gartner Hype Cycle’

  The gene therapy world is in turmoil, but Arbor, armed with more than $1 billion in partnerships and raises, is going forward.

  March 18, 2025

   · 

  4 min read

   · 

  Dan Samorodnitsky
• Press Releases

  SMSbiotech Receives Green Light for Phase I Clinical Trial in Australia, Targeting COPD

  March 18, 2025

   · 

  2 min read
• Press Releases

  MaaT Pharma Announces Positive Outcomes from Final DSMB Meeting for Pivotal Phase 3 Clinical Trial Evaluating MaaT013 in Acute Graft-versus-Host Disease

  March 18, 2025

   · 

  6 min read